KEMSA has received Kenya’s first batch of Lenacapavir HIV injectables, a twice-yearly shot that could transform HIV prevention, a major milestone in the fight against HIV/AIDS.

19/2/2026

Following an inspection of the commodity by a high-profile delegation from the Global Fund, NASCOP, National Treasury and other key partners this afternoon at the Supply Chain Centre Embakasi, the visit underscored national and global significance of this milestone.

It comes after the arrival of 21,000 starter doses, marking phase one of Kenya’s national rollout beginning March 2026 in 15 high-burden counties.

KEMSA Chief Executive Officer, Dr. Waqo Ejersa, acknowledged the partnership between Global Fund and KEMSA, noting that it has lasted for more than 24 years and that the Authority is fully capable of delivering the commodity nationwide. 

"Our partnership with Global Fund has stood strong for over 24 years and KEMSA remains fully committed and capable of ensuring that vital health commodities reach every corner of the country," said Dr. Waqo. 

He further stated that KEMSA has a robust, technology-driven distribution network capable of delivering Lenacapavir efficiently, safely and equitably to priority populations.

The Global Fund delegation led by the Executive Director - Peter Sands commended KEMSA’s strengthened supply chain systems, including enhanced digital visibility through the integrated Logistics Management Information System to improve traceability and accountability.

“We are impressed by the significant progress KEMSA has made in strengthening systems to support Kenya’s fight against HIV and AIDS,” he remarked. 

“KEMSA’s strengthened supply chain has enhanced digital visibility through the integrated iLMIS to boost traceability and accountability,” he added.

This partnership reinforces prevention of mother-to-child transmission efforts and advances the national goal of ensuring every child is born and remains HIV-free.

#KEMSA #HIVPrevention #Lenacapavir

KEMSA has received Kenya’s first batch of Lenacapavir HIV injectables, a twice-yearly shot that could transform HIV prevention, a major milestone in the fight against HIV/AIDS.
KEMSA has received Kenya’s first batch of Lenacapavir HIV injectables, a twice-yearly shot that could transform HIV prevention, a major milestone in the fight against HIV/AIDS.
KEMSA has received Kenya’s first batch of Lenacapavir HIV injectables, a twice-yearly shot that could transform HIV prevention, a major milestone in the fight against HIV/AIDS.
KEMSA has received Kenya’s first batch of Lenacapavir HIV injectables, a twice-yearly shot that could transform HIV prevention, a major milestone in the fight against HIV/AIDS.
KEMSA has received Kenya’s first batch of Lenacapavir HIV injectables, a twice-yearly shot that could transform HIV prevention, a major milestone in the fight against HIV/AIDS.